Department of Immunology, University of Manitoba, Winnipeg, MB, Canada.
Front Immunol. 2012 Aug 9;3:224. doi: 10.3389/fimmu.2012.00224. eCollection 2012.
The phosphoinositide 3-kinase (PI3K) pathway is a central signal transduction axis controlling normal B cell homeostasis and activation in humoral immunity. The p110δ PI3K catalytic subunit has emerged as a critical mediator of multiple B cell functions. The activity of this pathway is regulated at multiple levels, with inositol phosphatases PTEN and SHIP both playing critical roles. When deregulated, the PI3K pathway can contribute to B cell malignancies and autoantibody production. This review summarizes current knowledge on key mechanisms that activate and regulate the PI3K pathway and influence normal B cell functional responses including the development of B cell subsets, antigen presentation, immunoglobulin isotype switch, germinal center responses, and maintenance of B cell anergy. We also discuss PI3K pathway alterations reported in select B cell malignancies and highlight studies indicating the functional significance of this pathway in malignant B cell survival and growth within tissue microenvironments. Finally, we comment on early clinical trial results, which support PI3K inhibition as a promising treatment of chronic lymphocytic leukemia.
磷酸肌醇 3-激酶(PI3K)途径是控制体液免疫中正常 B 细胞稳态和激活的中央信号转导轴。p110δ PI3K 催化亚基已成为多种 B 细胞功能的关键介质。该途径的活性在多个水平上受到调节,肌醇磷酸酶 PTEN 和 SHIP 都发挥着关键作用。当失调时,PI3K 途径可导致 B 细胞恶性肿瘤和自身抗体产生。本综述总结了目前关于激活和调节 PI3K 途径的关键机制的知识,这些机制影响正常 B 细胞的功能反应,包括 B 细胞亚群的发育、抗原呈递、免疫球蛋白同种型转换、生发中心反应和 B 细胞无反应性的维持。我们还讨论了在某些 B 细胞恶性肿瘤中报道的 PI3K 途径改变,并强调了表明该途径在组织微环境中恶性 B 细胞存活和生长中的功能意义的研究。最后,我们对早期临床试验结果进行了评论,这些结果支持 PI3K 抑制作为慢性淋巴细胞白血病的一种有前途的治疗方法。